Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Disha Narang, M.D., director of obesity medicine at Endeavor Health in Skokie, IL
Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA
Research Use Notice
Phase II data showed weight loss of up to approximately 20% at 52 weeks, with monthly dosing that could offer meaningful convenience advantages over weekly injections
Researchers using tirzepatide before and after tracking tools should document changes in body composition, not just scale weight
US$ 25.96
US$ 21.27
US$ 21.66
US$ 25.53
US$ 24.72
US$ 22.05
US$ 24.56
